You just read:

BerGenBio: Encouraging I-O Clinical Data With Selective AXL Inhibitor Bemcentinib (BGB324) Supports its Potential as Cornerstone of Cancer Therapy

News provided by

BerGenBio ASA

29 Jan, 2018, 07:52 GMT